2023 Jun 02

New search has been performed

A search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register identified 56 new references potentially eligible for inclusion in the updated review.

We have included four new studies (20 new references) at this update (ALPINE2 2017; EARLY 2019; OPTIMIZE 2018; TORPEDO 2020), two of these were previously listed as ongoing (EARLY 2019; TORPEDO 2020). There were eight additional references to four already included studies (Proesmans 2013; Ratjen 2010; Taccetti 2012; Treggiari 2011).

We excluded five new studies (14 new references) (Bustamante 2014; Di Cicco 2014; Frost 2021; Hansen 2015; Herrmann 2017). We added 14 new references to 11 already excluded studies (Clancy 2013; Elborn 2015; Flume 2015a; Flume 2015b; Goss 2009; Konstan 2011; Mainz 2014; Prayle 2013; Ramsey 1999; Rietschel 2009; Schuster 2013).

We identified three new studies (one reference each) which are ongoing (EUCTR2007‐003868‐22‐FR; EUCTR2011‐006171‐19‐IT; EUCTR2015‐003881‐96‐IT).

2023 Jun 02

New citation required and conclusions have changed

Three new authors have joined the team: Sherie Smith, Nicola J Rowbotham and Alexander Yule.

After the inclusion of four new studies, we have updated our conclusions as follows:

"We found that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection with Pseudomonas aeruginosa. Eradication may be sustained for up to two years. There is insufficient evidence to determine whether antibiotic strategies for eradicating early P aeruginosa decrease mortality or morbidity, improve quality of life, or are associated with adverse effects compared to placebo or standard treatment. Four trials comparing two active treatments have failed to show differences in rates of eradication of P aeruginosa. One large trial has shown that intravenous ceftazidime with tobramycin is not superior to oral ciprofloxacin. There is still insufficient evidence to state which antibiotic strategy should be used for the eradication of early P aeruginosa infection in CF, but there is now evidence that intravenous therapy is not superior to oral antibiotics."

2020 Feb 27

Amended

Clarification statement added from Kevin Southern, Cystic Fibrosis Editor on 27 February 2020: This review was found by the Cochrane Funding Arbiters, post‐publication, to be noncompliant with the Cochrane conflict of interest policy, which includes the relevant parts of the Cochrane Commercial Sponsorship Policy. The review will be updated by February 2021; the update will have a majority of authors and lead author free of conflicts.

Current version (post‐publication): Simon Langton Hewer is the lead investigator on the ongoing trial Torpedo‐CF: Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis, he has no financial conflicts of interest.

Alan Smyth declares relevant activities of membership of a Raptor steering committee, consultancies for Raptor, Gilead, Vertex, Roche and PTC. Actavis provide support for CF team educational activities.

2014 Oct 29

New search has been performed

A search of the Group's CF Register identified 117 references for possible inclusion in the review.

Three references have been added to an already included trial (Proesmans 2013). One trial, known as the ELITE trial, has been moved from 'Ongoing studies' to 'Included studies' and the reference to the full publication added; this trial has provided a comparison of duration of intervention not previously available for inclusion (Ratjen 2010). A further trial also previously listed as ongoing with the study ID Ramsey 2005 (also known as the EPIC trial) has been included with 11 new references (Treggiari 2011). One new trial, with nine references has been included (Taccetti 2012).

A total of 22 new trials (97 references) have been excluded: one reference each (Alothman 2005; Goss 2009; Prayle 2013; Postnikov 2007; Wainwright 2011b); two references each (Alothman 2002; Kenny 2009; Mainz 2014; Schelstraete 2010; Tramper‐Stranders 2009); three references each (Coates 2011; Geller 2007; Mazurek 2012; Rietschel 2009); four references each (Retsch‐Bogart 2008; Trapnell 2012); five references each (Clancy 2013; Konstan 2010); six references each (Oermann 2009; Schuster 2013); 10 references (Retsch‐Bogart 2009); and 32 references (Ramsey 1999).

Two trials previously listed as 'Awaiting classification' have now been excluded (Latzin 2008; Lenoir 2007). One additional reference has been added to a previously excluded study (Wainwright 2011a)

The full paper to an abstract already listed as 'Awaiting Classification' has now been published and added to the existing study ID while we await clarification regarding participants from the authors (Noah 2010).

One new trial (with a single reference) has been added to 'Ongoing studies' (TORPEDO Trial).

There have been three post hoc changes to the review at this update:

• we now include participants who have received treatment within six months of the first isolation of P. aeruginosa (previously not more than two months);

• we now allow trials where all patients receive some eradication therapy before randomisation which reflects current recommended 'standard of care' and consequent trial design;

• we have added cost as an outcome measure, as cost‐effectiveness has become increasingly important in CF care.

2014 Oct 29

New citation required but conclusions have not changed

This review has been updated, but the conclusions remain the same.

2010 Oct 04

Amended

Contact details updated.

2008 Oct 28

Amended

Converted to new review format.

2017 May 10

Amended

Converted to new review format.